Yu-Zhi Lu
Overview
Explore the profile of Yu-Zhi Lu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
106
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuo C, Lin Y, Lo Y, Lu Y, Babuharisankar A, Lien H, et al.
iScience
. 2024 Sep;
27(9):110710.
PMID: 39262792
Mitochondria play important roles in cell fate, calcium signaling, mitophagy, and the signaling through reactive oxygen species (ROS). Recently, mitochondria are considered as a signaling organelle in the cell and...
2.
Liang L, Xiong L, He X, Song L, Wang X, Lu Y, et al.
Front Immunol
. 2024 Sep;
15:1371662.
PMID: 39221249
Background: The relationship between peripheral immune cells and immunoglobulin A nephropathy (IgAN) is widely known; however, causal evidence of this link is lacking. Here, we aimed to determine the causal...
3.
Wang M, Liu A, Niu Q, Feng X, Zheng Y, Chen S, et al.
Theranostics
. 2022 Jul;
12(10):4513-4535.
PMID: 35832075
Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible fibrotic disease with high mortality. Currently, pirfenidone and nintedanib are the only approved drugs for IPF by the U.S. Food and...
4.
Zhou L, Cheng P, He X, Liang L, Wang M, Lu Y, et al.
J Cell Physiol
. 2021 Jul;
237(1):566-579.
PMID: 34231213
Idiopathic pulmonary fibrosis (IPF) is defined as a specific form of chronic, progressive fibrosing interstitial pneumonia. It is unknown why fibrosis in IPF distributes in the peripheral or named sub-pleural...
5.
Lu Y, Liang L, Cheng P, Xiong L, Wang M, Song L, et al.
Am J Physiol Lung Cell Mol Physiol
. 2021 Mar;
320(6):L990-L1004.
PMID: 33787325
The distribution of fibrosis in idiopathic pulmonary fibrosis (IPF) is subpleural with basal predominance. Alveolar epithelial cell was considered as the key cell in the initial phase of IPF. However,...
6.
Lu Y, He X, Liu F, Cheng P, Liang L, Wang M, et al.
Exp Cell Res
. 2020 Sep;
396(1):112295.
PMID: 32971116
Idiopathic pulmonary fibrosis (IPF) is a fatal fibrosing interstitial lung disease with limited therapeutic options and a median survival of 3 years after diagnosis. Dysregulated epithelial regeneration is key event...
7.
Liu F, Yu F, Lu Y, Cheng P, Liang L, Wang M, et al.
Biochim Biophys Acta Mol Cell Res
. 2020 Aug;
1867(11):118806.
PMID: 32739525
Idiopathic pulmonary fibrosis (IPF) is a specific form of chronic, progressive and fibrosing interstitial pneumonia of unknown cause. The main feature of IPF is a heterogeneous appearance with areas of...
8.
Wang M, Xiong L, Jiang L, Lu Y, Liu F, Song L, et al.
EBioMedicine
. 2019 Mar;
41:670-682.
PMID: 30850350
Background: Pleural fibrosis is defined as excessive depositions of matrix components that result in pleural tissue architecture destruction and dysfunction. In severe cases, the progression of pleural fibrosis leads to...
9.
Zhou L, Wang M, Liu F, Lu Y, Song L, Xiong L, et al.
Toxicol Lett
. 2018 Dec;
303:1-8.
PMID: 30572104
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease that typically leads to respiratory failure and death. The cause of IPF is poorly understood. Although several environmental and occupational...
10.
Nie S, Zha L, Fan Q, Liao Y, Zhang H, Chen Q, et al.
Front Immunol
. 2018 Aug;
9:1775.
PMID: 30123216
The thymic stromal lymphopoietin (TSLP)/TSLP receptor (TSLPR) axis is involved in multiple inflammatory immune diseases, including coronary artery disease (CAD). To explore the causal relationship between this axis and CAD,...